Vivek Jayaraman Appointed as Cerus Corporation’s Chief Commercial Officer

Cerus Corporation (NASDAQ:CERS) announced today the appointment of Vivek Jayaraman as chief commercial officer, effective August 29th, 2016. Mr. Jayaraman joins Cerus from TriVascular Technologies, Inc. where he previously served as vice president of sales and marketing.

“I am pleased to add Vivek to the Cerus team,” said William ‘Obi’ Greenman, president and chief executive officer of Cerus. “With our progress to date with U.S. blood centers, including the American Red Cross, and preparation for our European launch of the INTERCEPT red cell system, it is now time to strengthen our global commercial leadership. Vivek has an impressive track record of success in both large and small organizations and possesses firsthand knowledge of what it takes to scale commercially. We look forward to the many contributions Vivek will bring to our mission of making INTERCEPT the global standard of care in transfusion medicine.”

Mr. Jayaraman led TriVascular’s commercial expansion as the company grew from a pre-clinical, venture-backed startup into a publicly traded, global medical device company. At the time of its merger with Endologix, Inc. (NASDAQ: ELGX) in February 2016, TriVascular’s products were sold in over 30 countries. Prior to TriVascular, Mr. Jayaraman served in roles of increasing responsibility at Medtronic, Inc.; most recently serving as vice president of global marketing for Medtronic’s endovascular innovations business. Mr. Jayaraman received his MBA from the Wharton School at the University of Pennsylvania and holds dual bachelor’s degrees from the University of Michigan.

“This is a great time to join Cerus, and I look forward to furthering the commercial success of INTERCEPT platelets and plasma, and preparing for the planned launch of INTERCEPT red cells,” said Mr. Jayaraman. “In light of events across the globe and concerns about blood safety, the corresponding need for INTERCEPT has never been greater. I am excited to work with the team to ensure that blood centers, hospitals, physicians and patients have access to INTERCEPT-treated blood components.”

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See www.cerus.com for more information about Cerus.

INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation.

Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus’ expectations regarding Cerus’ products, prospects and expected results, including statements concerning Mr. Jayaraman success as Cerus’ new chief commercial officer, the commercial success of the INTERCEPT Blood System and potential approval and future launch of the red blood cell system. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation: risks associated with Cerus’ ability to effectively integrate Mr. Jayaraman into its commercial team; the commercialization and market acceptance of, and customer demand for, the INTERCEPT Blood System; that Cerus may be unable to file for CE Mark approval of the red blood cell system in Europe in the anticipated timeframe or at all, and even if filed, Cerus may be unable to obtain CE Mark approval, or any other regulatory approvals, of the red blood cell system in a timely manner or at all, as well as other risks detailed in Cerus’ filings with the Securities and Exchange Commission, including in Cerus‘ Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, filed with the SEC on August 5, 2016. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160809005576/en/